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A B S T R A C T   
Objective: To determine the effect of frailty on Health Related Quality of Life (HRQoL) after treatment for Head 
and Neck Cancer (HNC). 
Materials and methods: Patients were prospectively included in OncoLifeS, a data-biobank. Before treatment, 
patients underwent geriatric screening, including the Groningen Frailty Indicator (GFI) and Geriatric 8 (G8). 
Patients’ HRQoL was measured using the European Organisation for Research and Treatment of Cancer Quality 
of Life Questionnaire Core 30 (EORTC-QLQ-C30) at three, six, twelve and twenty four months after treatment. 
Linear mixed models were used for statistical analysis. All models were adjusted for baseline HRQoL values, 
relevant confounders at baseline and yielded estimates (β), 95% confidence intervals and p-values. 
Results: 288 patients were included. The mean age was 68.4 years and 68.8% were male. During follow-up, 84 
patients had tumor recurrence and 66 died. Response to EORTC-QLQ-C30 ranged from 77.3% to 87.8%. Frail 
patients, defined by GFI, had significantly worse Global Health Status/Quality of Life (GHS/QoL) 
(β = −8.70(−13.54;−3.86), p  <  0.001), physical functioning (β = −4.55(−8.70;−0.40), p  <  0.032), 
emotional functioning (β = −20.06(−25.65;−15.86), p  <  0.001), and social functioning 
(β = −8.44(−13.91;−2.98), p  <  0.003) three months after treatment compared to non-frail patients. 
Furthermore, frail patients had a significantly worse course of GHS/QoL (β = −7.47(−11.23;−3.70), 
p = 0.001), physical functioning (β = −3.28(−6.26;−0.31), p = 0.031) and role functioning 
(β = −7.27(−12.26;-2.28), p = 0.005) over time, compared to non-frail patients. When frailty was determined 
by G8, frailty was significantly associated with worse GHS/QoL (β = −6.68(−11.00;−2.37), p = 0.003) and 
emotional functioning (β = −5.08(−9.43;−0.73), p = 0.022) three months after treatment. 
Conclusion: Frail patients are at increased risk for decline in HRQoL, and further deterioration during follow-up 
after treatment for HNC.   
Introduction 
With the incidence of cancer and specifically the proportion of el-
derly with cancer rising, oncologists may increasingly encounter the 
geriatric syndrome of frailty [1]. Frailty results from the heterogenic 
process of aging, leaving great diversity in populations with respect to 
physical, functional, psychological and social status, and is defined as ‘a 
state of increased vulnerability to poor resolution of homeostasis after a 
stressor event, which increases the risk of adverse outcomes’ [2]. Often, 
chronological age is not very representative of a patient’s biological 
age. One of the populations that is thought to be very frail are patients 
with Head and Neck Cancer (HNC). In this population, functional and 
cognitive impairment, depressive symptoms and social isolation have 
shown to be highly prevalent [3]. The burden of frailty in HNC patients 
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is higher than in patients with other solid malignancies [4]. Probably, 
general symptoms secondary to tumor extension and location, such as 
weight loss and malnutrition, contribute to this [5]. Additionally, pa-
tient related factors such as lifelong tobacco and alcohol abuse, which 
are etiological factors for HNC, increase frailty status as well [6,7]. 
For head and neck oncologists, this leads to a challenging clinical 
problem. On the one hand, intensive, often multimodal, treatment is 
indicated; on the other hand, patients may be vulnerable with multiple 
comorbidities, polypharmacy, functional and psychosocial restrictions. 
This makes decision making challenging. Ideally, by determining the 
biological age (i.e. frailty), undertreatment of fit elderly and over-
treatment of frail young patients should be prevented. The gold stan-
dard to assess frailty is a Comprehensive Geriatric Assessment (CGA) by 
a geriatrician [8]. Because of its time consuming nature, burden for the 
patient and limited health care capacity, screening tools have been 
developed to select patients that need CGA [9]. 
In HNC, frailty has already been associated with increased fre-
quency and severity of postoperative complications, prolonged length 
of hospital stay, increased readmission rates and worse overall survival  
[10]. Although these outcome measures are all clinically relevant, they 
do not represent the perspective of the patient. Older patients have 
different priorities regarding treatment outcome than their younger 
counterparts; e.g. Health Related Quality of Life (HRQoL) may be 
considered more important than survival in decision making [11–13]. 
Long-term HRQoL as reported by patients is increasingly considered 
a valuable outcome measure for cancer treatment. Previous studies 
showed that frailty is associated with worse HRQoL in other oncological 
cohorts [14–17]. However, this has never been investigated specifically 
in HNC patients. A more accurate prediction of patient-rated HRQoL 
may be of help in decision making and management of expectations. In 
the present prospective study, we investigated how frailty affects 
HRQoL shorty after treatment for HNC, and how frailty affects the 
course of HRQoL during long-term follow-up after treatment. 
Material and methods 
Study design 
The present study is a prospective observational cohort study with 
two years of follow-up. All patients were enrolled in OncoLifeS, a 
prospective oncological data-biobank at the (UMCG) [18]. OncoLifeS 
has been approved by the local Medical Ethical Committee and the 
study protocol was approved by the OncoLifeS scientific board. 
Study population 
Between October 2014 and May 2016, all consecutive patients re-
ferred to the UMCG with a mucosal, salivary gland or complex cuta-
neous malignancy (giant basal cell carcinoma, squamous cell carcinoma 
stage II or higher, melanoma, Merkel cell carcinoma and neck metas-
tasis of any cutaneous malignancy, requiring major surgery and/or 
radiotherapy) of the head and neck were asked to participate in 
OncoLifeS and were included after obtaining written informed consent 
(Fig. 1). Patients were seen at the outpatient clinics of the department 
of Otorhinolaryngology, Head and Neck Surgery, and the department of 
Oral and Maxillofacial Surgery. Patients were treated according to 
(inter)national guidelines and discussed within our multidisciplinary 
head and neck tumor board. Exclusion criteria were palliative treat-
ment, non-standard treatment (e.g. in the scope of other clinical trials) 
and missing baseline data on HRQoL (Fig. 1). As the burden of frailty is 
expected to be relatively high in young HNC patients as well, age was 
not an exclusion criterion in our study, in contrast to other studies in-
vestigating frailty. Tumor recurrence or death led to exclusion from the 
analyses from that time point onwards (Fig. 1). 
Data collection 
Patients’ age, sex, tumor site, histopathology, cancer stage, primary 
treatment and comorbidities were registered at baseline. Staging was 
done according to the seventh edition of the Union for International 
Cancer Control (UICC) TNM classification of malignant tumors [19]. 
Comorbidities were graded using the Adult Comorbidity Evaluation 
(ACE-27) as none, mild, moderate or severe [20]. As part of a geriatric 
screening at our outpatient clinic, within the scope of OncoLifeS, frailty 
status of patients was assessed using two validated frailty screening 
instruments. The Groningen Frailty Indicator (GFI), a fifteen-item 
questionnaire, was completed by patients either at the outpatient clinic 
or at home and returned by mail. Patients with a GFI score greater than 
or equal to four were considered frail [21]. The Geriatric 8 (G8), an 
eight-item scoring instrument, was completed by one of the in-
vestigators or a nurse together with the patient at the outpatient clinic. 
Patients with a G8 score lower than or equal to fourteen were con-
sidered as frail [22]. Although the intention of the study was purely 
observational, advancing insights of patients’ frailty status might have 
unconsciously led to referral to a geriatrician. 
As our primary measure of follow-up, patients were asked to report 
HRQoL using the European Organisation for Research and Treatment of 
Fig. 1. Flowchart diagram with the in- and exclusion of patients and follow-up 
statistics of the analyzed cohort. 
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Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30) before 
treatment and at three, six, twelve and twenty four months after 
treatment [23]. Global health status, functional scales, symptom scales 
and summary score were calculated according to the EORTC-QLQ-C30 
scoring manuals [24,25]. 
Statistical analysis 
All statistical procedures were performed with SPSS Statistics 23.0 
software (IBM, Armonk, New York, United States of America). Descriptive 
statistics were presented as mean  ±  standard deviation (SD), median 
(interquartile range) or frequency (percentage). Differences between 
groups were analyzed with T-test for normally distributed continuous data 
and χ2 test or Fisher’s exact test for categorical data. 
We employed Linear Mixed-effect Models (LMMs) for the analyses 
of repeated continuous measures, i.e. the EORTC-QLQ-C30 scales. 
LMMs are a superior method for analyzing large longitudinal datasets 
as they allow missing data points without discarding entire cases. An 
online available methods paper was used as a reference [26]. Typically, 
HRQoL decreases steeply during treatment, and then slowly tends to get 
better over time (Fig. 2a) [27]. Due to this irregular shape of trajectory, 
we only performed analysis on the three to twenty-four month interval, 
treating it as being linear (Fig. 2b). Leaving out polynomial terms 
makes interpreting coefficients possible and thus allows for assessing 
clinical relevance rather than a p-value. 
For the analyses, covariance type was set to unstructured. Fixed ef-
fects included the intercept and at least the variables time, frailty and 
frailty*time. Coefficients for frailty refer to the difference in HRQoL for 
frail and non-frail patients at three months after treatment. Coefficients 
for the interaction term frailty*time refer to the effect of frailty on 
change of HRQoL over time (per year). Coefficients yielded 95% con-
fidence intervals (CIs) and p-values. All models were adjusted for 
baseline differences between frail and non-frail patients, by adding the 
baseline score of dependent EORTC-QLQ-C30 scale to the model. 
Furthermore, all models were adjusted for age, sex, cancer stage, 
treatment modality and comorbidity as well as their interaction with 
time (coefficients not shown in table). For random effects an intercept 
was included for between subject differences and covariance type was 
unstructured. Estimation method was set to Maximum Likelihood (ML) 
and predicted values and standard error of predicted values were saved 




In this study, 288 patients were included. Follow-up and drop-out 
statistics are shown in Fig. 1. During follow-up, 84 patients developed 
recurrent disease and 66 patients died. Response rates for EORTC-QLQ- 
C30 remained stable throughout follow-up, averaging around 80%. 
Patient characteristics are presented in Table 1. The mean age was 
68.4 years and approximately two-thirds of patients were male. Most 
patients had mucosal cancer (79.5%), followed by skin malignancy 
(18.8%) and malignant salivary gland tumor (1.7%). Most patients 
(86.1%) had squamous cell carcinoma. The most common primary 
mucosal sites were oral cavity (25.7%), larynx (22.9%) and oropharynx 
(18.1%). Patients underwent either primary surgery (56.6%), radio-
therapy (28.8%) or chemoradiation (14.6%), or a combination of those. 
According to the GFI, 29.3% of patients were frail, while using the G8, 
54.7% were considered frail. Tumor site, histopathology, stage and 
treatment type did not differ between frail and non-frail patients; 
however, frail patients (both by GFI and G8) had significantly higher 
age and more severe comorbidity (Table 1). 
Frailty is associated with decline in quality of life 
Mean EORTC-QLQ-C30 scores at baseline and during follow-up are 
provided in Supplementary table 1 and 2. Frailty, measured by GFI was 
associated with significantly worse Global Health Status/Quality of Life 
Fig. 2. Quality of life during and after treatment for head and neck cancer. (a) Mean summary EORTC-QLQ-C30 score: a typical shape of quality of life trajectory. (b) 
Example of Global health status/QoL trajectory for the interpretation of linear mixed model analysis. Green (non-frail patients) and red (frail patients) lines indicate 
means. Dashed lines indicate predicted trajectory by the linear mixed model. # Refers to the difference in quality of life at 3 months after treatment (frail estimate in 
the models). * Refers to the different course of quality of life trajectories for frail and non-frail patients with respect to 1 year (frail*time estimate in the models). 
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(GHS/QoL) at three months after treatment 
(β = −8.70(−13.54;−3.86), p  <  0.001), but also with a further 
decline of GHS/QoL during two years after treatment 
(β = −7.47(−11.23;−3.70), p  <  0.001), in models adjusted for 
baseline and relevant covariates (Table 2 and Fig.  3a). Frailty measured 
by G8 was associated with worse GHS/QoL at three months after 
treatment (β = −6.68 (−11.00;−2.37), p = 0.003) as well, but not 
with a worse course over time (Table 2 and Fig.  3g). 
Frailty is associated with decline in functioning 
Frail patients, according to GFI, had worse physical 
(β = −4.55(−8.70;−0.40), p = 0.032), emotional 
(β = −10.92(−16.06;−5.79), p  <  0.001) and social functioning 
(β = −8.44 (−13.91;−2.98), p = 0.003) at three months after treatment 
than their non-frail counterparts, adjusted for baseline and covariates 
(Table 2 and Fig.  3b,d,f). Moreover, these patients showed a significant 
further decline of physical (β = −3.28(−6.26;−0.31), p = 0.031) and 
role functioning (β = −7.27(−12.26;−2.28), p = 0.005) over time, 
compared to non-frail patients (Table 2 and Fig.  3b,c). When frailty was 
measured by G8, only emotional functioning (β = −5.02(−9.43;−0.73), 
p = 0.022) was different between frail and non-frail patients at three 
months after treatment (Table 2 and Fig.  3j). 
Frailty is associated with increased symptom burden 
Frail patients, measured by GFI, showed more fatigue 
(β = 8.25(2.15;14.36), p = 0.008), pain (β = 10.09(5.05;15.13), 
p  <  0.001), dyspnea (β = 8.53(3.21;13.85), p = 0.002), insomnia 
(β = 8.07(1.35;14.79), p = 0.019), appetite loss 
(β = 14.23(−7.65;20.81), p  <  0.001), diarrhea (β = 4.58(1.16;8.01), 
p = 0.009), and financial difficulties (β = 7.36(2.80;11.93), 
p = 0.002) than non-frail patients in models adjusted for baseline and 
relevant covariates, at three months after treatment (Table 2). Ad-
ditionally, prolonged complaints of nausea and vomiting were seen in 
frail patients (β = 2.87(0.66;5.09), p = 0.011). Frailty, measured by 
the G8, was associated with more dyspnea (β = 5.02(0.14;9.90), 
p = 0.044), appetite loss (β = 7.21(1.03;13.39), p = 0.022), and 
diarrhea (β = 3.40(0.27;6.54), p = 0.033) at three months after 
treatment (Table 2). 
Table 1 
Patient characteristics of the included cohort (n = 288). Values given as n(%) unless otherwise specified. P-values given for a t-test b χ2 test or c Fisher’s exact test. 
ACE-27 = Adult Comorbidity Evaluation 27.          
Patient characteristics Groningen Frailty Indicator Geriatric 8 Total (n = 288) 
Baseline Non-frail (n = 203) Frail (n = 84) p-value Non-frail (n = 126) Frail (n = 152) p-value   
Age        
Mean  ±  SD 67.2  ±  10.6 71.4  ±  11.2 0.003a 65.8  ±  9.6 70.4  ±  11.7 0.001a 68.4  ±  10.9 
Median (interquartile range) 67.2 (59.6–75.4) 69.1 (62.5–80.7)  66.0 (59.4–73.3) 69.2 (62.4–79.4)  68.2 (60.6–76.7)         
Sex        
Male 142 (70.0) 55 (65.5) 0.457b 95 (75.4) 96 (63.2) 0.028b 198 (68.8) 
Female 61 (30.0) 29 (34.5)  31 (24.6) 56 (36.8)  90 (31.3)         
Reason for referral        
Primary tumor 190 (93.6) 78 (92.9) 0.819b 117 (92.9) 143 (94.1) 0.680b 269 (93.4) 
Recurrent tumor 13 (6.4) 6 (7.1)  9 (7.1) 9 (5.9)  19 (6.6)         
Tumor site        
Oral cavity 52 (25.6) 22 (26.2) 0.377c 30 (23.8) 41 (27.0) 0.327c 74 (25.7) 
Nasal cavity and paranasal sinus 13 (6.4) 2 (2.4)  8 (6.3) 7 (4.6)  16 (5.6) 
Nasopharynx 4 (2.0) 0 (0.0)  3 (2.4) 1 (0.7)  4 (1.4) 
Oropharynx 36 (17.7) 16 (19.0)  24 (19.0) 28 (18.4)  52 (18.1) 
Hypopharynx 5 (2.5) 4 (4.8)  2 (1.6) 7 (4.6)  9 (3.1) 
Larynx 44 (21.7) 22 (26.2)  36 (28.6) 29 (19.1)  66 (22.9) 
Salivary glands 3 (1.5) 2 (2.4)  1 (0.8) 4 (2.6)  5 (1.7) 
Skin 38 (18.7) 16 (19.0)  19 (15.1) 32 (21.1)  54 (18.8) 
Unknown primary tumor 8 (3.9) 0 (0.0)  3 (2.4) 3 (2.0)  8 (2.8)         
Histopathology        
Squamous Cell Carcinoma 172 (84.7) 76 (90.5) 0.196b 110 (87.3) 129 (84.9) 0.561b 248 (86.1) 
Other 31 (15.3) 8 (9.5)  16 (12.7) 23 (15.1)  40 (13.9)         
Stage        
I 51 (25.8) 20 (23.8) 0.987b 36 (28.6) 31 (21.1) 0.368b 71 (24.7) 
II 40 (20.2) 18 (21.4)  27 (21.4) 28 (19.0)  58 (20.1) 
III 28 (14.1) 12 (14.3)  15 (11.9) 24 (16.3)  40 (13.9) 
IV 79 (39.9) 34 (40.5)  48 (38.1) 64 (43.5)  114 (39.6)         
Primary treatment        
Surgery 117 (57.7) 45 (53.6) 0.455b 70 (55.6) 86 (56.6) 0.498b 163 (56.6) 
Postoperative radiotherapy 42 (20.7) 18 (21.4)  22 (17.5) 38 (25.0)  61 (21.2) 
Postoperative chemoradiation 4 (2.0) 1 (1.2)  3 (2.4) 2 (1.3)  5 (1.7) 
Radiotherapy 53 (26.1) 30 (35.7)  35 (27.8) 45 (29.6)  83 (28.8) 
Chemoradiation 33 (16.3) 9 (10.7)  21 (16.7) 21 (13.8)  42 (14.6)         
ACE-27        
No comorbidity 55 (27.1) 7 (8.3) 0.000b 37 (29.4) 24 (15.8) 0.000b 62 (21.5) 
Mild comorbidity 71 (35.0) 31 (36.9)  52 (41.3) 47 (30.9)  102 (35.4) 
Moderate comorbidity 54 (26.6) 21 (25.0)  25 (19.8) 45 (29.6)  76 (26.4) 
Severe comorbidity 23 (11.3) 25 (29.8)  12 (9.5) 36 (23.7)  48 (16.7) 
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Discussion 
To our knowledge, this is the first study examining the association 
between frailty and changes in HRQoL after treatment in HNC patients. 
Key findings include that frailty, identified by two different frailty 
screening tools, was associated with a decline in QoL, different func-
tioning domains, and increased symptom burden after treatment for 
HNC, independently of other relevant factors. Moreover, frailty at 
baseline was also associated with further deterioration of QoL and 
functioning during two years of follow-up. These findings emphasize 
Fig. 3. Predicted values and standard error of predicted values by linear mixed models for EORTC-QLQ-C30 scales. a-f = frailty defined by Groningen Frailty 
Indicator. g-l = frailty defined by Geriatric 8. 
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the importance of implementing frailty screening in treatment coun-
seling and decision making. 
As we expected, frail patients showed worse GHS/QoL after treat-
ment than non-frail patients, regardless of their baseline score, and age, 
sex, cancer stage, treatment modality and comorbidity. This was not 
only the case at three months after treatment, but their trajectory in-
creasingly diverged from non-frail patients during the two years of 
follow-up. This effect was most pronounced when frailty was measured 
by using the GFI and may roughly be interpreted in two ways: either the 
frail patients’ GHS/QoL trajectory deteriorates over time compared to 
non-frail patients, or recovery for frail patients is not as good as for non- 
frail patients. Plotted trajectories (Fig.  3a) reveal that this is a com-
bination of both deterioration and worse recovery, however, this should 
be interpreted for each EORTC-QLQ-C30 scale independently. 
Although only a minor difference (8.70 points) on the GHS/QoL 
scale between frail and non-frail patients was found at three months 
after treatment (Table 2, frail term), adding the increase per year (7.47 
points, Table 2, frail*time term) resulted in a major cumulative differ-
ence (21.77 points) two years after treatment, which was adjusted for 
confounding factors. This is seen in plotted trajectories as well (Fig.  
3a). According to classification of Osoba et al. (5–10 points difference 
should be interpreted as ‘little’ change, 10–20 points as ‘moderate’ 
change and  >  20 as ‘ very much’ change), the relative decrease in 
GHS/QoL is clinically highly relevant [28]. These findings could have a 
major impact on decision making: being aware of poorer outcomes for 
frail patients may and should be taken into account during shared de-
cision making. 
Comparing our results with published literature, a similar analysis 
Table 2 
Results of linear mixed model analysis. Frailty measured by Groningen Frailty Indicator and Geriatric 8 alters quality of life after treatment. Frail refers to the main 
effect (difference in score of frail patients with respect to non-frail patients at 3 months). Frail*Time refers to the interaction of frailty and time, indicating the amount 
of change in Quality of Life over time (with respect to 1 year) for frail compared to non-frail patients. a All models were adjusted for baseline differences in 
corresponding EORTC-QLQ-C30 scale, and age, sex, stage, treatment modality and comorbidity and their interaction with time.            
EORTC-QLQ-C30  Groningen Frailty Indicator a Geriatric 8 a 
Scale Parameters Estimate (β) 95% CI p-value Estimate (β) 95% CI p-value  
Summary score Frail −6.12 −9.57 −2.67  <  0.001 −2.87 −5.84 0.10 0.058  
Frail*Time −1.70 −4.28 0.88 0.191 −0.74 −2.65 1.18 0.448           
Global health status/QoL Frail −8.70 −13.54 −3.86  <  0.001 −6.68 −11.00 −2.37 0.003  
Frail*Time −7.47 −11.23 −3.70  <  0.001 −2.39 −5.55 0.77 0.138           
Functional scales                    
Physical functioning Frail −4.55 −8.70 −0.40 0.032 −1.85 −5.43 1.74 0.311  
Frail*Time −3.28 −6.26 −0.31 0.031 −1.36 −3.76 1.03 0.262           
Role functioning Frail −5.70 −12.42 1.02 0.096 −5.31 −11.22 0.59 0.078  
Frail*Time −7.27 −12.26 −2.28 0.005 −2.57 −6.49 1.36 0.198           
Emotional functioning Frail −10.92 −16.06 −5.79  <  0.001 −5.08 −9.43 −0.73 0.022  
Frail*Time 2.07 −2.45 6.60 0.367 0.41 −3.05 3.86 0.817           
Cognitive functioning Frail −3.88 −8.13 0.37 0.074 −2.59 −6.38 1.20 0.180  
Frail*Time −0.89 −4.31 2.54 0.610 −0.44 −3.29 2.41 0.761           
Social functioning Frail −8.44 −13.91 −2.98 0.003 −2.78 −7.51 1.95 0.248  
Frail*Time −2.73 −6.77 1.30 0.183 −2.68 −6.02 0.65 0.114           
Symptom scales                    
Fatigue Frail 8.25 2.15 14.36 0.008 4.58 −0.90 10.07 0.101  
Frail*Time 3.59 −0.74 7.92 0.104 1.26 −2.23 4.75 0.475           
Nausea and vomiting Frail 1.46 −1.55 4.47 0.340 0.34 −2.42 3.10 0.809  
Frail*Time 2.87 0.66 5.09 0.011 2.13 −0.23 4.49 0.077           
Pain Frail 10.09 5.05 15.13  <  0.001 4.57 −0.11 9.26 0.056  
Frail*Time 3.31 −1.53 8.15 0.178 0.03 −3.97 4.03 0.988           
Dyspnoea Frail 8.53 3.21 13.85 0.002 5.02 0.14 9.90 0.044  
Frail*Time 0.14 −4.01 4.30 0.946 0.49 −2.86 3.84 0.773           
Insomnia Frail 8.07 1.35 14.79 0.019 4.13 −1.76 10.03 0.169  
Frail*Time −3.45 −8.91 2.01 0.214 −0.37 −4.87 4.12 0.871           
Appetite loss Frail 14.23 7.65 20.81  <  0.001 7.21 1.03 13.39 0.022  
Frail*Time −2.99 −8.29 2.31 0.267 −1.12 −5.61 3.37 0.623           
Constipation Frail 3.25 −1.26 7.77 0.157 0.01 −4.07 4.09 0.996  
Frail*Time −0.25 −3.90 3.39 0.891 −0.53 −3.64 2.57 0.736           
Diarrhoea Frail 4.58 1.16 8.01 0.009 3.40 0.27 6.54 0.033  
Frail*Time 0.67 −3.13 4.46 0.730 0.08 −3.05 3.21 0.959           
Financial difficulties Frail 7.36 2.80 11.93 0.002 3.72 −0.47 7.91 0.082  
Frail*Time 0.89 −3.08 4.85 0.660 1.68 −1.62 4.98 0.315 
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was recently performed by Kirkhus et al. in a heterogeneous oncological 
cohort [17]. Frailty, assessed using a modified geriatric assessment, was 
associated with worse GHS/QoL but not with further decline over time 
during twelve months follow-up [17]. However, this study did not ad-
just for baseline differences between frail and non-frail patients, which 
have been shown to be significant at baseline already [29]. This may 
explain the larger estimates than in our present study. Other studies 
that have addressed frailty with respect to GHS/QoL did not find sig-
nificant differences in the breast cancer and colorectal cancer popula-
tion [15,16]. Only one study included a small proportion of HNC pa-
tients (4.3%) and found within a frail population (based on G8) that 
several factors such as stage, pain, fatigue, nutrition and comorbidity 
were associated with decline in GHS/QoL [30]. Though, the study po-
pulation was very heterogeneous, analyses were unadjusted for dif-
ferent treatment modalities and lacked long-term follow-up. 
An important contributor to patients’ HRQoL is the level of func-
tioning. Physical functioning has been demonstrated to be worse in 
older patients after treatment for HNC [31]. In our study, after ad-
justing for age, frailty was associated with worse physical functioning 
both shortly after treatment as well as with further deterioration during 
follow-up. Literature data on this issue is heterogeneous [15–17,32], 
but most importantly, not investigated in HNC. Differences between 
cohort characteristics and research methodology may largely explain 
differences. 
Role functioning is often overlooked in literature and rarely in-
vestigated as a primary outcome measure with respect to frailty. In our 
study, frailty (GFI) was strongly associated with decline in role func-
tioning over time. When reviewing the EORTC-QLQ-C30 questions in-
volved in role functioning ‘Were you limited in doing either your work or 
other daily activities?’ and ‘Were you limited in pursuing your hobbies or 
other leisure time activities?’, these seem important matters for QoL. 
Emotional functioning was significantly worse for frail (GFI and G8) 
patients three months after treatment. Since frailty is a multi-
dimensional geriatric syndrome including a significant psychological 
domain as well, this was to be expected: patients with premorbid psy-
chological issues have a higher risk of developing psychological pro-
blems during and after treatment [33]. Improvement of emotional 
functioning after treatment occurred in both frail and non-frail patients 
(Fig.  3d,j), despite the known high prevalence of fear of recurrence, 
depression and even high suicide risk in the HNC population in other 
studies [34–36]. 
Cognitive functioning was not significantly affected by treatment or 
by frailty during follow-up in our study. Another study investigating 
HNC patients treated with radiotherapy, however, did show significant 
decline of cognitive function within seven years after treatment [37]. 
Probably, their objective assessment of cognitive function is much more 
sensitive to cognitive alterations than the patient-reported cognitive 
functioning scale, employed in our study. These results should therefore 
be interpreted with care [38]. 
Social functioning is specifically at risk in HNC treatment due to the 
diseases’ relation with the organs for communication [39,40]. We found 
frail (GFI) patients to have worse social functioning than non-frail pa-
tients shortly after treatment, but both groups gradually improved in 
the following years, similar to data in literature [41]. 
Clearly, large differences exist between screening tools such as GFI 
and G8. This leads to the question: which are the most important do-
mains of a geriatric screening with respect to changes in QoL? G8 is 
known as a very physically oriented screening tool with more than half 
of the questions related to nutrition, weight loss and comorbidities [9]. 
G8 is strongly associated with surgical complications as well as survival 
in oncological cohorts, but the relation with HRQoL has rarely been 
investigated [42]. In our study, G8 showed a weaker association with 
HRQoL than GFI. The GFI covers larger functional and psychosocial 
domains of frailty [9] which are, apparently, superior in long-term 
patient reported outcomes. Some studies have already investigated se-
parate domains of geriatric screening in relation to QoL in more 
heterogeneous oncological cohorts: one found comorbidity and nutri-
tion to be associated with decline in QoL after three months and an-
other showed associations of malnutrition [30], depression and im-
paired mobility with decline in QoL after six months [43]. 
It has been difficult to show the objective benefit of implementing a 
geriatric screening in standard oncological healthcare with outcomes 
such as adverse events, QoL or survival [44,45]. Though, it has been 
shown that treatment recommendations are significantly different when 
an onco-geriatric multidisciplinary team is involved in decision making  
[12]. This does not necessarily mean that we should stop treating frail 
patients. After all, frail patients do not regret the decision that was 
made more than non-frail patients [46], but identification of vulner-
abilities may open doors to pre-treatment optimization or a more pa-
tient-tailored treatment plan. Prehabilitation studies are currently being 
carried out, also in the field of HNC. 
The main strengths of this study include the prospective inclusion of 
a relatively large cohort, the use of well-known validated ques-
tionnaires to address frailty and HRQoL, and a notable two years of 
follow-up. Solid statistical analysis was performed handling missing 
data well and therefore limiting bias, and also controlling for baseline 
differences and confounders. Some limitations may be the relative 
heterogeneity of the cohort, which includes mucosal, salivary gland and 
cutaneous tumors, and possibly underrepresentation of the frailest pa-
tients. Inclusion of frail patients remains difficult due to refusal to 
participate, inability (being overburdened) to undergo geriatric 
screening or non-responses to questionnaires [47]. 
Conclusion 
Frailty is significantly associated with decline in QoL and func-
tioning after treatment for HNC and even further deterioration in the 
long-term. Screening for frailty is highly recommended in the HNC 
population, as it may have implications for decision making or pre- 
treatment optimization. 






Appendix A. Supplementary material 
Supplementary data to this article can be found online at https:// 
doi.org/10.1016/j.oraloncology.2020.105020. 
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